What Happened?
Shares of global pharmaceutical company Eli Lilly (NYSE: LLY) jumped 2.4% in the afternoon session after the stock continued to rally as the company announced an additional $4.5 billion investment to expand its U.S. manufacturing capabilities as it prepares for surging demand for its weight-loss medications.
This brings Eli Lilly's total capital investment in its home state of Indiana to $21 billion since 2020. The company stated the expansion is necessary to meet the anticipated demand for its medicines, particularly its new weight-loss pill called Foundayo.
Adding to the positive sentiment, a recent clinical trial for Foundayo (also known as orforglipron) showed it produced significant weight loss in adults aged 65 and older, with a safety profile similar to that seen in younger patients. This news follows a period of strong performance, with sales of its existing drug, Mounjaro, surging by over 280% in Japan in the previous calendar year, highlighting the intense global appetite for these treatments.
After the initial pop the shares cooled down to $991.58, up 2.5% from previous close.
Is now the time to buy Eli Lilly? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Eli Lilly’s shares are not very volatile and have only had 9 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The previous big move we wrote about was 11 days ago when the stock gained 4.3% on the news that the stock continued to rally as the company reported strong first-quarter 2026 financial results that surpassed analyst expectations and raised its full-year guidance.
The pharmaceutical giant announced that its first-quarter revenue grew 56% to $19.8 billion, significantly beating analyst forecasts. This growth was driven by soaring demand for its popular GLP-1 drugs, Mounjaro and Zepbound, which generated a combined $12.8 billion in sales. The strong performance led to a 156% increase in non-GAAP earnings per share.
Citing this momentum, Eli Lilly raised its full-year revenue forecast to a range of $82 billion to $85 billion and boosted its earnings guidance. Adding to the positive sentiment, the FDA proposed a rule that would prohibit compounding facilities from making copycat versions of the company's key drugs, further protecting its market.
Eli Lilly is down 8.2% since the beginning of the year, and at $991.58 per share, it is trading 10.7% below its 52-week high of $1,110 from November 2025. Despite the year-to-date decline, investors who bought $1,000 worth of Eli Lilly’s shares 5 years ago would now be looking at an investment worth $5,132.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
